Neurofibromatosis type 1: Should we screen for other genetic syndromes? A case report of co-existence with multiple endocrine neoplasia 2A

European Journal of Clinical Investigation

Volumn 39, Issue 9, 2009, Pages 828-832

  Gkaliagkousi, E ^a   Erlic, Z ^b   Petidis, K ^a   Semertzidis, P ^a   Doumas, M ^a   Zamboulis, C ^a   Neumann, H P H ^b   Douma, S ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Multiple Endocrine Neoplasia 2A; Neurofibromatosis Type1; Pheochromocytoma; Von Hippel Lindau Syndrome

Indexed keywords

ADRENAL GLAND; AGED; ARTICLE; CASE REPORT; FEMALE; GENE MUTATION; GENETIC ANALYSIS; GENETIC DISORDER; GENETIC SCREENING; HUMAN; HYPERPARATHYROIDISM; NEUROFIBROMATOSIS; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTO ONCOGENE; SIPPLE SYNDROME; THYROID CANCER; VON HIPPEL LINDAU DISEASE;

AGED; FEMALE; GENETIC TESTING; GERM-LINE MUTATION; HUMANS; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS 1; PEDIGREE; PRACTICE GUIDELINES AS TOPIC;

EID: 68349129967     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2009.02174.x     Document Type: Article

References (24)

1. McClatchey AI. Neurofibromatosis. Annu Rev Pathol 2007 2 : 191 216.
2. Rosenberg NL, Diliberti JH, Andrews AM, Buist NR. Myotonic dystrophy and hyperparathyroidism: association with neurofibromatosis and multiple endocrine adenomatosis type 2A. J Neurol Neurosurg Psychiatry 1988 51 : 1578 80.
3. Freimanis MG, Rodgers RW, Samman NA. Neurofibromatosis and primary hyperparathyroidism. South Med J 1984 77 : 794 5.
4. Kodama H, Iihara M, Okamoto T, Obara T. Water-clear cell parathyroid adenoma causing primary hyperparathyroidism in a patient with neurofibromatosis type 1: report of a case. Surg Today 2007 37 : 884 7.
5. Griffiths DF, Williams GT, Williams ED. Multiple endocrine neoplasia associated with von Recklinghausen's disease. Br Med J (Clin Res Ed) 1983 287 : 1341 3.
6. Altinova AE, Toruner F, Cimen AR, Karakoc A, Atasever T, Yetkin I et al. The association of neurofibromatosis, bilateral pheochromocytoma and primary hyperparathyroidism. Exp Clin Endocrinol Diabetes 2007 115 : 48 70.
7. Al-Wahhabi B. Parathyroid adenoma and bilateral pheochromocytoma in a patient with neurofibromatosis. Ann Saudi Med 2005 25 : 255 7.
8. Moiton MP, Bijou F, Vargas F, Valentino R, Gruson D, Hilbert G et al. Association of type 1 neurofibromatosis and primary hyperparathyroidism. Presse Med 2002 31 : 1604 5.
9. Abdel-Wanis ME, Kawahara N, Tomita K. The association of neurofibromatosis 1 and spinal deformity with primary hyperparathyroidism and osteomalacia: might melatonin have a role? J Orthop Sci 2001 6 : 193 8.
10. Vogelzang PJ, Oates E, Bankoff MS. Parathyroid adenoma associated with neurofibromatosis: correlative scintigraphic and magnetic resonance imaging. Clin Nucl Med 1989 14 : 168 70.
11. Cotesta D, Erlic Z, Petramala L, Verrienti A, Cavallaro G, Giustini S et al. Coincidence of neurofibromatosis type 1 and multiple endocrine neoplasia type 2 (MEN 2). Endocrinologist 2008 18 : 277 81.
12. Ng PC, Henikoff S. Predicting the effects of amino acid substitutions on protein function. Annu Rev Genomics Hum Genet 2006 7 : 61 80.
13. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003 31 : 3812 4.
14. Gutmann DH, Aylsworth A, Carey JC, Korf B, Marks J, Pyeritz RE et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997 278 : 51 7.
15. Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Evans DG et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007 44 : 81 8.
16. Swinburn BA, Yeong ML, Lane MR, Nicholson GI, Holdaway IM. Neurofibromatosis associated with somatostatinoma: a report of two patients. Clin Endocrinol (Oxf) 1988 28 : 353 9.
17. Segni M, Massa R, Bonifacio V, Tartaglia F, Pucarelli I, Marzullo A et al. Thyroid C-cell hyperplasia in an adolescent with neurofibromatosis type 1. Horm Res 2001 56 : 63 6.
18. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M et al. Germline NF1 mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007 92 : 2784 92.
19. Raue F, Frank-Raue K. Multiple endocrine neoplasia type 2: 2007 update. Horm Res 2007 68 (Suppl. 5 101 4.
20. Koch CA, Vortmeyer AO, Zhuang Z, Brouwers FM, Pacak K. New insights into the genetics of familial chromaffin cell tumors. Ann N Y Acad Sci 2002 970 : 11 28.
21. Arao T, Okada Y, Tanikawa T, Inatomi H, Shuin T, Fujihira T et al. A case of von Hippel-Lindau disease with bilateral pheochromocytoma, renal cell carcinoma, pelvic tumor, spinal hemangioblastoma and primary hyperparathyroidism. Endocr J 2002 49 : 2181 8.
22. Lesueur F, Cebrian A, Robledo M, Niccoli-Sire P, Svensson KA, Pinson S et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006 66 : 1177 80.
23. Fernández RM, Navarro E, Antiñolo G, Ruiz-Ferrer M, Borrego S. Evaluation of the role of RET polymorphisms/haplotypes as modifier loci for MEN 2, and analysis of the correlation with the type of RET mutation in a series of Spanish patients. Int J Mol Med 2006 17 : 575 81.
24. Robledo M, Gil L, Pollán M, Cebrián A, Ruíz S, Azañedo M et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003 63 : 1814 7.